All In Biotech

Drug Trial Radar · NCT05018806

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Proof-of-concept Study Evaluating Efficacy and Safety of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Who Are Inadequate Responders or Intolerant to Topical Corticosteroids

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Sep 9, 2021

Primary completion

Jun 23, 2023

Study completion Jun 23, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or inadequate response to topical corticosteroids (TCS). The total study duration per participant was expected to be approximately 21 weeks, including up to 4 weeks of screening, 16 weeks of on-treatment double-blind period, 1 week of post-treatment follow-up.

Conditions

  • Atopic Dermatitis

Interventions

  • PlaceboDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • RilzabrutinibDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline (Day 1) to Week 16

Locations

31 sites in 7 countries. Site status is shown where the registry gives one.

  • Antelope Valley Clinical Trials Site Number : 8400001

    Northridge, California

  • Asthma and Allergy Associates, PC Site Number : 8400008

    Colorado Springs, Colorado

  • Florida International Research Center Site Number : 8400002

    Miami, Florida

  • Skin Sciences, PLLC Site Number : 8400005

    Louisville, Kentucky

  • DS Research of Kentucky, LLC Site Number : 8400004

    Louisville, Kentucky

  • Integrative Skin Care of MS/SKYCRNG Site Number : 8400011

    Ridgeland, Mississippi

  • National Allergy and Asthma Research, LLC. Site Number : 8400007

    North Charleston, South Carolina

  • Orion Clinical Research Site Number : 8400003

    Austin, Texas

  • E.P.I.M.R.D dba Western Sky Research, Inc. Site Number : 8400009

    El Paso, Texas

  • Investigational Site Number : 1240004

    Québec, Canada

  • Investigational Site Number : 1240008

    Red Deer, Alberta, Canada

  • Investigational Site Number : 1240013

    Greater Sudbury, Ontario, Canada

  • Investigational Site Number : 1240001

    London, Ontario, Canada

  • Investigational Site Number : 1240002

    Markham, Ontario, Canada

  • Investigational Site Number : 1240011

    Toronto, Ontario, Canada

  • Investigational Site Number : 1240007

    Toronto, Ontario, Canada

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 2030004

    Olomouc, Czechia

  • Investigational Site Number : 2030003

    Pardubice, Czechia

  • Investigational Site Number : 2030002

    Pilsen, Czechia

  • Investigational Site Number : 2030001

    Prague, Czechia

  • Investigational Site Number : 2760001

    Bad Bentheim, Germany

  • Investigational Site Number : 2760002

    Friedrichshafen, Germany

  • Investigational Site Number : 5280001

    Utrecht, Netherlands

  • Investigational Site Number : 6160008

    Chojnice, Poland

  • Investigational Site Number : 6160002

    Lodz, Poland

  • Investigational Site Number : 6160004

    Warsaw, Poland

  • Investigational Site Number : 6160001

    Lodz, Lódzkie, Poland

  • Investigational Site Number : 6160005

    Gdansk, Pomeranian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.